Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.
Avidity Biosciences Q4 EPS $(0.88) Beats $(0.89) Estimate, Sales $2.77M Beat $2.31M Estimate
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.89) by 1.12 percent. This is a 7.32 percent decrease over losses of $(0.82) per share from
Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock
Raymond James has upgraded Dyne Therapeutics Inc (NASDAQ:DYN) from Outperform to Strong Buy and raised the price target to $27 from $16.…
Credit Suisse Maintains Outperform on Avidity Biosciences, Raises Price Target to $35
Credit Suisse analyst Judah Frommer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $33 to $35.
Raymond James Maintains Strong Buy on Avidity Biosciences, Raises Price Target to $71
Raymond James analyst Steven Seedhouse maintains Avidity Biosciences (NASDAQ:RNA) with a Strong Buy and raises the price target from $30 to $71.
Tesla, Amazon, Novavax, Lennar Corp, Avidity Biosciences: Why These 5 Stocks Are Drawing Retail Investors’ Attention Today
Major Wall Street indices closed in the red on Wednesday despite an anticipated 50 basis points hike by the Federal Reserve as Chair Jerome Powell indicated the need for more data before the central bank could
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Raymond James Maintains Strong Buy on Avidity Biosciences, Raises Price Target to $71
Raymond James analyst Steven Seedhouse maintains Avidity Biosciences (NASDAQ:RNA) with a Strong Buy and raises the price target from $30 to $71.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) stock increased by 137.8% to $0.6 during Wednesday’s regular session. Trading volume for Vallon…